I-Mab
Anti-CD73 anti-PD-L1 bispecific antibodies

Last updated:

Abstract:

Provided are bispecific antibodies capable of binding to human CD73 protein and human PD-L1 protein. These bispecific antibodies are effective in treating cancer.

Status:
Grant
Type:

Utility

Filling date:

25 Jul 2019

Issue date:

15 Jun 2021